• +1-646-491-9876
    • +91-20-67278686

    Search

    Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2017

    Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2017

    • Report Code ID: RW0001767473
    • Category Pharmaceuticals
    • No. of Pages 163
    • Publication Month Apr-17
    • Publisher Name Global Markets Direct
    Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2017, provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline landscape.

    Post-Polycythemia Vera Myelofibrosis (PPV-MF) is a myeloproliferative blood cancer in which the bone marrow makes too many red blood cells. It may also result in the overproduction of white blood cells and platelets. Symptoms include heart attack, stroke, deep venous thrombosis, Headaches, lack of concentration and fatigue. The disease may be controlled by chemotherapy, transfusions, transplant and medications.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 10, 4 and 1 respectively.

    Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Overview
    Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Companies Involved in Therapeutics Development
    Celgene Corp
    CTI BioPharma Corp
    F. Hoffmann-La Roche Ltd
    Gilead Sciences Inc
    Incyte Corp
    Italfarmaco SpA
    JW Pharmaceutical Corp
    MedImmune LLC
    MEI Pharma Inc
    Merck & Co Inc
    Nippon Shinyaku Co Ltd
    Novartis AG
    Pfizer Inc
    Promedior Inc
    Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Drug Profiles
    buparlisib hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CWP-291 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    durvalumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    givinostat - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    glasdegib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    idelalisib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    itacitinib adipate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LCL-161 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NS-018 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pacritinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pembrolizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pomalidomide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pracinostat - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PRM-151 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sonidegib phosphate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    vismodegib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Dormant Projects
    Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Discontinued Products
    Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Product Development Milestones
    Featured News & Press Releases
    Dec 10, 2015: Promedior Presents Positive Phase 2 Data for PRM-151 in Myelofibrosis at ASH Annual Meeting
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Celgene Corp, H1 2017
    Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by CTI BioPharma Corp, H1 2017
    Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Gilead Sciences Inc, H1 2017
    Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Incyte Corp, H1 2017
    Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Italfarmaco SpA, H1 2017
    Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by JW Pharmaceutical Corp, H1 2017
    Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by MedImmune LLC, H1 2017
    Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by MEI Pharma Inc, H1 2017
    Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Merck & Co Inc, H1 2017
    Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Nippon Shinyaku Co Ltd, H1 2017
    Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Novartis AG, H1 2017
    Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Pfizer Inc, H1 2017
    Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Promedior Inc, H1 2017
    Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Dormant Projects, H1 2017
    Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Celgene Corp
    CTI BioPharma Corp
    F. Hoffmann-La Roche Ltd
    Gilead Sciences Inc
    Incyte Corp
    Italfarmaco SpA
    JW Pharmaceutical Corp
    MedImmune LLC
    MEI Pharma Inc
    Merck & Co Inc
    Nippon Shinyaku Co Ltd
    Novartis AG
    Pfizer Inc
    Promedior Inc

    Request for Sample

    Report Url http://www.reportsweb.com//post-polycythemia-vera-myelofibrosis-ppv-mf-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//post-polycythemia-vera-myelofibrosis-ppv-mf-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//post-polycythemia-vera-myelofibrosis-ppv-mf-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments